Improving the Efficacy of Conventional Therapy by Adding Andrographolide Sulfonate in the Treatment of Severe Hand, Foot, and Mouth Disease: A Randomized Controlled Trial
Table 2
Outcomes for participants with severe HFMD involved in a randomized trial comparing the efficacy of Andrographolide Sulfonate combination therapy with conventional therapy alone.
Variable
Conventional therapy group ()
Andrographolide sulfonate combination therapy group ()
Treatment difference (95% CI)
value
Primary Major complications, (%)
14 (12.1)
3 (2.6)
9.4 (2.8 to 16.1)
0.006
Respiratory failure, (%)
5 (4.3)
2 (1.8)
2.6 (−1.9 to 7.0)
0.45
Circulatory failure, (%)
1 (0.9)
—
0.9 (−0.8 to 2.5)
1.00
Purulent meningitis, (%)
1 (0.9)
—
0.9 (−0.8 to 2.5)
1.00
Brainstem encephalitis, (%)
1 (0.9)
—
0.9 (−0.8 to 2.5)
1.00
Encephalomyelitis, (%)
1 (0.9)
—
0.9 (−0.8 to 2.5)
1.00
Encephalitis, (%)
2 (1.7)
1 (0.9)
0.9 (−2.1 to 3.8)
1.00
Neurogenic pulmonary edema, (%)
2 (1.7)
—
1.7 (−0.6 to 4.1)
0.50
Pulmonary haemorrhage, (%)
1 (0.9)
—
0.9 (−0.8 to 2.5)
1.00
Secondary
Fever clearance time (SD),
96.9 (63.2)
69.1 (62.4)
27.8 (11.2, 44.4)
0.001
HFMD-cause deaths, (%)
1 (0.86)
—
0.9 (−0.8 to 2.5)
1.00
Duration of hospitalization (SD),
7.6 (2.0)
7.7 (1.7)
−0.1 (−0.5 to 0.4)
0.70
The healing time of typical skin or oral mucosa lesions (SD),
5.2 (1.6)
4.3 (1.5)
1.0 (0.6 to 1.4)
<.001
Adverse event, (%)
1 (0.86)
—
0.9 (−0.8 to 2.5)
1.00
*Values are means with standard deviations. †Surviving patients only. ‡defined as the number of days in the total-contact cast until the skin or oral mucosa completely closed.
